1,010 results on '"Shah, Payal"'
Search Results
102. Agency as Negotiation: Social Norms, Girls’ Schooling and Marriage in Gujarat, India
103. Resistance to PI3K Pathway Inhibition
104. Cute Kid? Patient Obesity Status and the Use of Nonmedical Descriptors in Presentations by Pediatric Residents.
105. Acceptability of artificial intelligence-based retina screening in general population
106. Epinephrine in the Bottle: Intraoperative vascular changes seen with intravitreal epinephrine
107. Human rights approaches to reducing infertility
108. Electronic medical record documentation of germline genetic evaluations in patients with ovarian cancer
109. Progressive myoclonus and neuroregression – a dreadful combination
110. TABLE 3 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
111. Supplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
112. Supplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
113. FIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
114. TABLE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
115. TABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
116. TABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
117. TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
118. FIGURE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
119. Data from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
120. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
121. Analytical validation of a multi-cancer early detection test with cancer signal origin using a cell-free DNA–based targeted methylation assay
122. Supplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma
123. Supplementary Tables 1-3 from EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer
124. Supplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma
125. Data from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma
126. Supplementary Data from A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
127. Correction: Angiopoetin-2 Signals Do Not Mediate the Hypervascularization of Islets in Type 2 Diabetes
128. Abstract P5-08-01: Pilot study of a patient-reported outcome (PRO) measurement strategy to determine impact of screening for minimal residual disease (MRD) in high-risk breast cancer survivors
129. Abstract OT2-09-01: TBCRC-055: A Phase II Study of NirAparib, Dostarlimab, and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR) – NCT04837209
130. Abstract ED2-1: Cancer risks in patients with moderate penetrance gene mutations
131. Coats' disease - Prognostic factors for globe and vision salvage in children, a long-term experience
132. Partnerships and appropriation: translating discourses of access and empowerment in girls’ education in India
133. Permanent and Temporary Policy Incentives for Conservation under Stochastic Returns from Competing Land Uses
134. Spaces to Speak: Photovoice and the Reimagination of Girls' Education in India
135. Dermatologists’ Role in the Diagnosis and Management of Coronavirus Disease 2019 Coagulopathy
136. Imputation models and error analysis for phase contrast MR cerebral blood flow measurements
137. Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients
138. Software to manage regulatory workflows for medical device development at academic medical centers: A critical gap
139. PMDedu: Assessing the educational needs of startups and academic investigators focused on pediatric medical device development
140. TIQ Comparator Based 8-bit Flash ADC for Communication Applications
141. Self-Driving Cars: Simulation, Issues and Possible Solutions for Implementation in India
142. Smart Contracts For NGOs and Startups using Blockchain
143. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3
144. Creating Intentional Spaces for Sustainable Development in the Indian Trans-Himalaya: Reconceptualizing Globalization from Below
145. Effectiveness of Kanna photoscreener in detecting amblyopia risk factors
146. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
147. Modified e-Delphi Process for the Selection of Patient-Reported Outcome Measures for Children and Families With Type 1 Diabetes Using Continuous Glucose Monitors: Delphi Study
148. Cute Kid? Patient Obesity Status and the Use of Nonmedical Descriptors in Presentations by Pediatric Residents
149. Patient- and County-Level Factors Associated with Late-Stage Merkel Cell Carcinoma at Diagnosis
150. 644 Major pathologic response after a single radiotherapy fraction + a single pembrolizumab dose given preoperatively in patients with cT1N0 triple negative breast cancer (TNBC) – preliminary results of a phase 1b/2 study (NCT04454528)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.